Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to greatly extend the lives of patients with cancer. The Company’s proprietary DfuseRxSM platform technology creates novel immune-based therapeutic products that can directly kill tumors and stimulate a strong adaptive immune response in certain cancer types. This approach is a new and emerging field of cancer treatment known as in situ vaccination.
Who we are
Intensity Therapeutics is a clinical development stage company. We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.